tbuckley/cabot-search huggingface dataset:
Could Grape Seed Extract Be an Alternative Treatment in the Management of Hot Flashes?
Authors: Kadri Altundag
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
MBRS-55. MOLECULAR CLASSIFICATION OF MEDULLOBLASTOMAS: NANOSTRING nCOUNTER ASSAY VS A COMBINATION OF IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN-SITU HYBRIDISATION
Authors: Kavneet Kaur, Pankaj Pathak, Prerana Jha, Ajay Garg, Vaishali Suri, Mehar C Sharma, Ashish Suri, Chitra Sarkar
Journal: Neuro-Oncology (2018)
EMBR-03. TREATMENT OF EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES (ETMR) WITH TARGETED RADIOIMMUNOTHERAPY
Authors: Kayleen Bailey, Neeta Pandit-Taskar, John Humm, Pat Zanzonico, Stephen W Gilheeney, Kim Kramer
Journal: Neuro-Oncology (2018)

Embryonal Tumor/Multilayered Rosettes (ETMR) is an aggressive CNS tumor in young children; median survival is 12 months. We explored the use of intraventricular 131I-8H9 targeting B7-H3 in patients with ETMR on a trial at MSK. Patients received 2 mCi 131I-8H9 as a tracer followed by 1 or 2 therapeutic 131I-8H9 injections. Dosimetry was based on serial CSF, blood samplings and region of interest (ROI) on nuclear scans. Brain and spine MRIs and CSF cytology were done at baseline, 5 weeks after 131I-8H9, and approximately every 3 months thereafter. Acute toxicities and survival were noted. Three symptomatic children (ages 14 months, 3 and 3.5 years) had large parietal masses confirmed to be B7-H3+ ETMR. Patients received surgery, focal radiation, and high dose chemotherapy. Patients 1 and 2 received 131I-8H9 (80 and 53 mCi, respectively). Patient 3 had a local recurrence prior to 131I-8H9 treated with surgery, craniospinal radiation, chemotherapy, then 131I-8H9 (36 mCi). 131I-8H9 was well-tolerated; patient 2 had grade 4 thrombocytopenia 1 month after injection. Mean dose delivered by 131I-8H9 was 68.4 cGy/mCi to CSF and 1.95 cGy/mCi to blood. Mean ROI doses were 230.4 (ventricular) and 58.2 (spinal) cGy/mCi. Patients 1 and 2 remain in remission 5.5 and 1.2 years after diagnosis, respectively. Patient 3 suffered a third local recurrence 22 months after diagnosis and remains alive with disease. 131I-8H9 appears safe with favorable dosimetry therapeutic index. When used as consolidation following surgery and chemoradiation therapy, 131I-8H9 may have therapeutic benefit for patients with ETMR.
Simultaneous Micropatterning of Fibrous Meshes and Bioinks for the Fabrication of Living Tissue Constructs
Authors: Mylène de Ruijter, Alexandre Ribeiro, Inge Dokter, Miguel Castilho, Jos Malda
Journal: Advanced Healthcare Materials (2018)

Fabrication of biomimetic tissues holds much promise for the regeneration of cells or organs that are lost or damaged due to injury or disease. To enable the generation of complex, multicellular tissues on demand, the ability to design and incorporate different materials and cell types needs to be improved. Two techniques are combined: extrusion-based bioprinting, which enables printing of cell-encapsulated hydrogels; and melt electrowriting (MEW), which enables fabrication of aligned (sub)-micrometer fibers into a single-step biofabrication process. Composite structures generated by infusion of MEW fiber structures with hydrogels have resulted in mechanically and biologically competent constructs; however, their preparation involves a two-step fabrication procedure that limits freedom of design of microfiber architectures and the use of multiple materials and cell types. How convergence of MEW and extrusion-based bioprinting allows fabrication of mechanically stable constructs with the spatial distributions of different cell types without compromising cell viability and chondrogenic differentiation of mesenchymal stromal cells is demonstrated for the first time. Moreover, this converged printing approach improves freedom of design of the MEW fibers, enabling 3D fiber deposition. This is an important step toward biofabrication of voluminous and complex hierarchical structures that can better resemble the characteristics of functional biological tissues.
MBCL-35. CURRENT PROGNOSTIC FACTORS AND TREATMENT RESULTS IN YOUNG CHILDREN MEDULLOBLASTOMAS
Authors: Ekaterina Salnikova, Sergey Ozerov, Anastasiya Ektova, Marina Ryzhova, Andrey Korshunov, Aleksey Nechesnyuk, Artur Merishavyan, Svetlana Gorbatykh, Elena Erega, Aleksander Shapochnik, Aleksander Karelin, Ella Kumirova, Aleksander Rumyantsev
Journal: Neuro-Oncology (2018)

Current diagnostic capabilities will enable to modify risk-group and individualize treatment of medulloblastomas. To evaluate treatment results of 93 patients under 5y (median=41m) with primarily diagnosed medulloblastomas depending on the current risk factors. We retrospectively analyzed the data of 93 patients, who are observed in Rogachev’s Center from June 2001 till Marth 2017. Molecular genetic testing was performed in all cases (DKFZ/Germany): Gr3/Gr4/SHH was diagnosed in 41/17/35 cases. MYC/MYCN-amplification/17q-gain/17q-loss/i17/PTCH1-mutation/MGMT/P53-mutation=8/8/41/28/21/11/3/2 cases. HIT 2000/2008 treatment regimen used in 45 patients. Gr3: M0/M+/Mx=14/26/1, R0/R+/Rx=29/7/5, classic/anapl/desmo=23/14/4, without/with-VPS=27/14, without/with-regionalMTX/no data=31/9/1, with/without-RT=31/10, PD=19 cases, are alive 18 patients. Gr4: M0/M+/Mx=6/9/2, R0/R+=13/4, classic/anapl/desmo=13/3/1, without/with-VPS=27/14, without/with-regionalMTX=15/2, with/without-RT=16/1, PD=3 cases, are alive 12. SHH: M0/M+/Mx=20/12/3, R0/R+/Rx=25/5/5, classic/anapl/desmo=6/2/27, without/with-VPS=28/7, without/with-regionalMTX=21/14, with/without-RT=16/19, PD=13 cases, are alive 20. 5y-OS in Gr3/Gr4/SHH=0.52/0.76/0.72 (р=0.04). 5y-PFS in Gr3/Gr4/SHH=0.5/0.82/0.6 (р=0.09). PFS with/without MYC and MYCN-amplification 0.12/0.65 (p=0.001) and 0.57/0.6 (p=0.89); with/without 17q-loss and 17q-gain 0.41/0.69 (p=0.007) and 0.57/0.63 (p=0.32); with/without P53 and PTCH1-mutations 0.5/0.61 (p=0.71) and 0.8/0.58 (p=0.21); with/without i17=0.5/0.63 (p=0.16); with/without MGMT=1.0/0.59 (p=0.15). Gr3-PFS: 12-36m/36-60m=0.42/0.54 (p=0.36); R+/R0=0.39/0.47 (p=0.49); М0/М+=0.71/0.42 (р=0.12); classic/anapl/desmo=0.62/0.33/0.5 (р=0.04); without/with-VPS=0.54/0.45 (p=0.32); without/with-regionalMTX=0.55/0.44 (p=0.71); without/with-RT=0.14/0.61 (p=0.02). Gr4-PFS: 12-36m/36-60m=1.0/0.81 (p=0.64); R+/R0=0.25/1.0 (p<0.001); М0/М+=1.0/0.78 (р=0.26); classic/anapl/desmo=0.76/1.0/1.0 (р=0.34); without/with-VPS=0.94/0.0 (p=0.002); without/with-localMTX=0.85/0.67 (p=0.52); without/with-RT=1.0/0.81 (p=0.64). SHH-PFS: <12m/12-36m/36-60m=0.0/0.54/0.8 (p=0.39); R+/R0=0.8/0.62 (p=0.55); М0/М+=0.57/0.75 (р=0.2); classic/anapl/desmo=0.6/0.5/0.62 (р=0.95); without/with-VPS=0.7/0.21 (p=0.09); without/with-regionalMTX=0.6/0.62 (p=0.98); without/with-RT=0.42/0.81 (p=0.02). Statistically significantly worse PFS-values were obtained: in patients with MYC amplification/17q loss; in Gr3 with LCA-tumor/without RT; in Gr4 with R0/VPS; in SHH without RT. Key words: medulloblastomas, children, molecular and genetic groups, treatment results
QOL-49. ACADEMIC ACHIEVEMENT PREDICTION AND OUTCOMES IN CHILDREN WITH BRAIN TUMORS
Authors: Hannah McAtee, Sheila Barron, Natalie Denburg, Amanda Grafft, Timothy Ginader, Charles Lynch, Mariko Sato
Journal: Neuro-Oncology (2018)

The purpose of our study is to identify patterns of academic achievement in children before diagnosis of a brain tumor and to examine longitudinal trends of academic achievement after the treatment, by utilizing two state-wide databases: The Iowa Testing Program (ITP) and Iowa Cancer Registry (ICR). The ITP uses a set of standardized academic achievement measures designed for students from kindergarten through high school, while the ICR has records of patients with a brain tumor diagnosis since 1973. A deterministic linkage of the ICR and ITP databases was performed to identify target samples. We identified 593 children with brain tumors who performed academic assessment between 2000-2016. Median age at diagnosis was 9 years old (ranges 0-20). Of the 593 children, 37% had malignant tumors (N=219), and 62% had benign tumors (N=370). Achievement data, in the form of percentile rank scores by grade and content domains (e.g., reading, mathematics) were analyzed. We found no significant difference in academic achievement levels between patients with benign versus malignant tumors at the year prior to diagnosis. Additionally, we found no statistically significant trajectory of academic achievement prior to diagnosis for tumor type, looking specifically at medulloblastoma for our malignant exemplar and low-grade glioma for our benign exemplar. We also found a statistically significant difference in academic achievement trajectory after treatment for those patients who received radiation, rather than chemotherapy, surgery, or combination treatment.
Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG)
Authors: R. Peixoto, R. Riechelmann, G. Prolla, R. Weschenfelder, J. Rego, G. Dos Santos Fernandes, G. Pereira, M. de Oliveira, D. da Rocha Filho, A. Coutinho
Journal: Annals of Oncology (2018)

Introduction: Tumor sidedness and RAS/BRAF status have changed the treatment landscape of metastatic colorectal cancer (mCRC). This study was performed to understand the first line choices of Brazilian oncologists for patients with advanced/unresectable metastatic colorectal cancer (mCRC), especially in the emergent context of tumor sidedness and RAS/BRAF V600E status. Methods: This is a cross-sectional electronic survey composed of 6 questions, which was sent to Brazilian medical oncologists and medical oncology groups by email, Facebook and/or WhatsApp. The survey instrument assessed current practices in terms of first-line treatment choices for fit patients with mCRC, including left-sided wild-type (wt)-RAS/wt-BRAFV600E, right-sided wt-RAS/wt-BRAFV600E and any-side mutated RAS, considering that all drugs were available. The instrument also elicited data about years in practice in Medical Oncology, gender and how much of each oncologist's practice was dedicated to gastrointestinal tumors (GI). Those with at least 75% of their time dedicated to patients with GI malignancies were considered specialists. The questionnaire was open for answers for 12 days. Results: The survey was completed during a 12-day period by 222 medical oncologists from across the country. Because the survey was not sent to all individual emails, we could not estimate the response rate but for those who responded, the completion rate was 100%. Most oncologists were male (57.2%) and were in Oncology practice for less than 10 years (61.7%). Only 9.4% of the participants were specialists in GI tumors. For left-sided, wt-RAS/wt-BRAFV600E mCRC, most oncologists (81.9%) chose first line chemotherapy (CT) + anti-EGFR therapy, with 53.2% of them preferring FOLFIRI as the CT backbone. Meanwhile, for right-sided, wt-RAS/wt-BRAFV600E mCRC, the majority (71.1%) would offer CT + bevacizumab (53.7% with FOLFOX, 31.6% with FOLFIRI and 14.5% with FOLFOXIRI). For mutated-RAS mCRC, most oncologists (51.8%) decided for FOLFOX + bevacizumab (33.6% for FOLFIRI + bevacizumab and 14.5% for FOLFOXIRI + bevacizumab). Conclusion: This is the first study conducted among Brazilian oncologists to investigate treatment preferences according to sidedness and RAS/BRAF V600E status. Our survey indicates that tumor sidedness influences the choice of both CT backbone and monoclonal antibody in unresectable wt- RAS mCRC.
Common Threads in Pediatric Inflammatory Diseases
Authors: Trusha T. Patel, Maire A. Conrad, Judith R. Kelsen
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES
Authors: Michaël Meel, Mark de Gooijer, Kenn Zwaan, Piotr Waranecki, Marjolein Breur, Levi Buil, Tonny Lagerweij, Laurine Wedekind, Jos Twisk, Jan Koster, Rintaro Hashizume, Eric Raabe, Ángel Montero Carcaboso, Marianna Bugiani, Olaf van Tellingen, Dannis van Vuurden, Gertjan Kaspers, Esther Hulleman
Journal: Neuro-Oncology (2018)

Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brainstem cancer that is thought to originate from primitive neural stem cells, and is characterized by the frequent presence of mutations in histone 3 genes. Biopsy studies have shown that a large subset of DIPG possesses a mesenchymal phenotype, likely contributing to the diffuse growth pattern and inherent therapy resistance of these tumors. Recently, the receptor tyrosine kinase AXL has been identified both as an important player in the mesenchymal transition and as a hallmark of neural stem cells. In this study, we demonstrate that AXL is a driver of the mesenchymal and stem-like phenotype of DIPG cells and as such, is a promising therapeutic target. Inhibition of AXL by the small molecule BGB324, in combination with the HDAC inhibitor panobinostat, potently and synergistically decreases cell viability and migration of primary DIPG cultures, and reverses their mesenchymal and stem-like phenotype. Moreover, this combination treatment leads to decreased expression of important genes involved in DNA repair, and a strong radiosensitizing effect on DIPG cultures. Pharmacokinetic studies further reveal that BGB324 is capable of crossing the blood-brain barrier and can reach therapeutic concentrations in mouse brain. Consequently, we demonstrate that treatment of DIPG xenograft bearing mice with BGB324 and panobinostat results in a decrease in tumor load and extended survival. Altogether, our study shows that AXL is an important player in DIPG biology and demonstrates the promising therapeutic potential of the combination of BGB324 and panobinostat for the treatment of DIPG.
Effects of plantar reflexology on sleep and quality of life in patients with breast cancer undergoing chemotherapy and hormonal therapies.
Authors: Stefano Magno, Elena Cappai, Francesco Dentale, Stefania Carnevale, Daniela Belella, Assunta Scaldaferri, Alessio Filippone, Riccardo Masetti
Journal: Journal of Clinical Oncology (2017)

e21697 Background: In the last decade, several studies have shown the role that integrative therapies (e.g. acupuncture, herbal medicine, body-mind practices) can play to relieve symptoms related to cancer and its mainstream treatment. However, conclusive evidence about the value of Plantar Reflexology (PR) on side effects management in breast cancer patients is still lacking. Methods: Forty-four breast cancer patients, treated at Catholic University Hospital’s Breast Unit, were enrolled and invited to complete the Pittsburgh Sleep Quality Index (PSQI) and the Quality of Life index (QL). Afterward, they were randomized into two groups: 23 patients were treated with 6 weekly sessions of PR (1 hour each) conducted by a specialist (experimental arm), while the other 21 underwent standard medical treatment alone (control arm). At the end of treatment sessions, PSQI and QL were re-administered in both groups. Results: A Multivariate Analysis of Covariance (MANCOVA) was conducted, including the participation to experimental vs. control group as an independent variable, PSQI and QL post-test scores as dependent variables, PSQI and QL pre-test scores and patients’ age as covariates. Results showed that PR improved significantly the quality of sleep [F(1, 39) = 4.94, p &lt; .05)], but no significant effects emerged on the quality of life. A further MANCOVA, conducted on the subscales of the PSQI, showed significant mean differences in sleep disturbances [F(1, 34) = 4.38, p &lt; .05), sleep latency [F(1, 34) = 4.88, p &lt; .05) and sleep quality [F(1, 34) = 6.92, p &lt; .05) in favor of the experimental group. Conclusions: Results suggest that PR may relieve sleep difficulties typically linked to mainstream therapies for breast cancer. No effects of PR emerged for patients’ quality of life, although the small sample tested does not allow to draw any definitive conclusion. These promising results encourage further investigations about the beneficial role of PR. In our initial experience, PR appears as easy, well-tolerated and safe procedure, that can play a role in the management of symptoms that are poorly controlled by conventional pharmacological treatments.
EPEN-27. PERIOPERATIVE OUTCOMES IN PEDIATRIC EPENDYMOMAS – A RETROSPECTIVE ANALYSIS OF 47 PATIENTS
Authors: Vikas Singh, Abhay Kattepur, Aditya Patil, Prakash Shetty, Tejpal Gupta, Girish Chinnaswamy, Sridhar Epari, Rakesh Jalali, Ali Asgar Moiyadi
Journal: Neuro-Oncology (2018)

AIM: To analyze clinico-dermographic profiles and outcome in pediatric population diagnosed with ependymoma. MATERIALS AND Pediatric (<18years) patients diagnosed with ependymoma from January 2010 to December 2015 were retrospectively analyzed. All charts, files and electronic medical records of these patients were studied. The demographic, surgical, pathological and follow up data (atleast 2 years) of these patients were collected and analyzed using SPSS version 20 software. During the study period, 47 pediatric patients were diagnosed with ependymoma. Mean age at diagnosis was 7.7 years with male: female ratio of 1.2: 1. Raised intracranial tension was most common presentation seen in 55.31% (n=26). 65.96% (n=31) had received some form of prior treatment (Surgery/Radiotherapy/Chemotherapy). Supratentorial location was seen in 51% (n=24). Gross total resection was achieved in 63.83% (n=30). Anaplastic ependymoma was most common histologic subtype seen in 76.6% (n=36). Post operatively adjuvant treatment (radiotherapy +/- chemotherapy) was administered to 72.34 %(n= 34). During follow up, 46.81% (n=22) patients were alive without disease while 25.53% (n=12) succumbed to the disease. In the alive without disease group, 86.36% (n=19) had undergone gross total resection. A subset analysis between grade III and grade II ependymoma showed statistical significant difference for pre-operative neurological deficits (p=0.04) and incidence of surgical site infections. (p=0.03) while there was no difference in peri-operative morbidity and mortality between the two groups. Surgery followed by adjuvant treatment in anaplastic ependymoma is associated with long term disease free survival.
IMMU-03. TARGETING THE CD200 CHECKPOINT BLOCKADE FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS
Authors: Elisabeth Pluhar, Elisabet Ampudia-Mesias, Zhengming Xiong, Christopher Moertel, Michael Olin
Journal: Neuro-Oncology (2018)

Glioblastoma multiforme is an incurable primary brain tumor. To address this dismal outcome, aggressive interventions need to be pursued. Recently, the FDA approved immune checkpoint inhibitor therapy for solid tumors that are otherwise refractory to standard therapy heralding a new era for effectively treating cancer. Yet, immune checkpoint inhibitors yield poor responses for patients with glioblastoma, calling into question whether cancer immunotherapy can be applied to glioblastoma. We are targeting an alternative checkpoint blockade. The CD200 checkpoint blockade is a paired inhibitory and activation receptors. Targeting these receptors activate antigen presenting cells enhancing dendritic cell maturation, cytokine production and antigen specific T cell activation, which significantly extend survival in two murine glioma models. In addition, in an ongoing pilot study using dogs diagnosed with high-grade glioma, patients receiving a canine specific CD200 peptide inhibitor in combination with the autologous tumor lysate vaccine had enhanced survival past 820 days, relative to 214 days with lysate alone Currently, 25% of the dogs are alive past 810 days post-surgery. Death due to tumor recurrence was observed in 8 dogs (40%); 6 dogs (30%) died of non-tumor related deaths. In contrast, 100% of the dogs in the tumor-lysate-only group died of tumor recurrence. Furthermore, serum chemistry profiles showed that the peptide did not induce any systemic toxicity. Importantly, we developed human CD200 inhibitors demonstrating strong immune responses. Our humanized inhibitors activate CD14 cells, and enhances cytokine secretion, enhance dendritic cell maturation enhances, and antigen-specific immune responses.